Immune checkpoint inhibitor-associated sarcoidosis reaction
Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys. One of the infrequent irAEs associated with ICIs is sarcoidosis, an in...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Society of Diabetic Nephropathy Prevention
2023-09-01
|
| Series: | Journal of Nephropathology |
| Subjects: | |
| Online Access: | https://nephropathol.com/PDF/jnp-12-e21520.pdf |
| Summary: | Immune checkpoint inhibitors (ICIs) constitute a class of drugs that stimulate the immune system to fight cancer cells. However, they can also induce immune-related adverse events (irAEs) in various organs, including the kidneys. One of the infrequent irAEs associated with ICIs is sarcoidosis, an inflammatory disease that can impact multiple organs, such as the lungs, skin, and lymph nodes. Sarcoidosis is characterized by the formation of granulomas, clusters of immune cells that can potentially harm tissues. In some cases, ICIs can trigger kidney sarcoidosis, leading to impaired renal function. The mechanism through which ICIs initiate sarcoidosis is believed to involve activating T cells and cytokines that foster inflammation. |
|---|---|
| ISSN: | 2251-8363 2251-8819 |